What is the recommended shingles vaccine series, including dosing schedule, contraindications, and alternatives, for adults?

Shingles Vaccine Series Recommendations

Adults aged 50 years and older should receive a 2-dose series of recombinant zoster vaccine (RZV/Shingrix) administered 2-6 months apart, regardless of prior shingles history or previous live zoster vaccine (ZVL/Zostavax). 1

Dosing Schedule

The standard RZV series consists of:

• Dose 1: Initial administration
• Dose 2: Given 2-6 months after the first dose (minimum interval: 4 weeks)
• If the second dose is administered too soon (before 4 weeks), it should be repeated 1
• Important: Second doses given beyond 6 months (even up to 12+ months) remain effective and do not require restarting the series 2

Real-world data shows approximately 70% of patients complete the second dose within 6 months and 80% within 12 months 3. The delayed second dose does not significantly impair vaccine effectiveness 2.

Age-Based Recommendations

Ages 50 and Older (Immunocompetent)

• RZV is strongly recommended as a 2-dose series 1, 4
• While FDA-licensed for ages 50+, ACIP specifically recommends starting at age 60 for routine vaccination in older guidelines 5, 6, though the most recent 2020 guidance supports vaccination starting at age 50 1
• Vaccination should proceed even if the patient reports prior herpes zoster infection 1

Ages 19-49 (Immunocompromised)

• RZV is recommended for adults aged ≥19 years who are or will be immunocompromised due to disease or therapy 7
• This expanded indication was approved by FDA in 2021 and recommended by ACIP in October 2021 7
• Uptake remains low in this younger immunocompromised population (only 2.0% by 2023) 8

Special Populations

Immunocompromised Patients

RZV is safe and recommended for patients with:

• HIV infection (regardless of CD4 count) 1, 7
• Solid organ transplant recipients
• Hematopoietic stem cell transplant recipients
• Autoimmune conditions (rheumatoid arthritis, lupus, inflammatory bowel disease)
• Cancer patients receiving chemotherapy
• Patients on immunosuppressive medications 7, 9

Key advantage: RZV is a non-live vaccine, making it safe for immunocompromised individuals, unlike the older live ZVL vaccine which was contraindicated in this population 4, 10.

Pregnancy

• RZV is not recommended during pregnancy due to lack of safety data 1
• Consider delaying vaccination until after pregnancy if otherwise indicated 1
• ZVL is contraindicated in pregnancy 1

Prior Vaccination History

• If previously received ZVL (Zostavax): Administer RZV at least 2 months after ZVL 1
• RZV is preferred over ZVL due to superior efficacy (>90% vs. lower efficacy with ZVL) 4, 10

Contraindications

Absolute Contraindications

• Severe allergic reaction to any vaccine component
• For ZVL only: severe immunodeficiency states, pregnancy 1

Not Contraindicated

• Prior herpes zoster infection
• Chronic medical conditions (diabetes, heart disease, lung disease, renal disease)
• Serologic evidence of varicella susceptibility (vaccination does not require prior varicella immunity testing) 1

Vaccine Effectiveness

RZV demonstrates superior real-world effectiveness:

• 2-dose series: 70.1% effectiveness against herpes zoster 2
• 1-dose series: 56.9% effectiveness (emphasizing importance of completing both doses) 2
• Against postherpetic neuralgia: 76.0% effectiveness 2
• Efficacy remains >90% in clinical trials and is well-preserved in adults ≥70 years 4
• Minimal waning over 4 years of follow-up 4

Common Pitfalls to Avoid

1. Don't delay the second dose unnecessarily: While 2-6 months is recommended, doses given later (even 12+ months) are still effective—complete the series rather than restart 2

2. Don't skip vaccination in immunocompromised patients: RZV is specifically designed for and recommended in this population 7

3. Don't require varicella immunity testing: Serologic evidence of prior varicella is not necessary before administering RZV 1

4. Don't withhold vaccination due to prior shingles: Previous herpes zoster infection is not a contraindication; vaccinate regardless 1

5. Recognize missed opportunities: 96% of patients who received only one dose had subsequent healthcare visits where the second dose could have been administered, with 36% receiving other vaccines during that time 3

Practical Implementation

• Pharmacy administration increases completion rates: First doses given in pharmacies are associated with higher series completion 8
• Patient education is critical: Financial concerns and lack of awareness remain significant barriers 11
• Younger immunocompromised adults (19-49 years) have particularly low uptake and require targeted outreach 8